Summary
‘Pharming’ can be defined as the use of transgenic animals or plants for the production of pharmaceutical proteins or peptides. Since the 1980s it has been proclaimed as an efficient and cost-effective method for the production of biopharmaceuticals. In 2006, the first therapeutic product produced in the milk of transgenic livestock gained approval, ATryn®, a recombinant form of human antithrombin III, produced by GTC Biotherapeutics. This was an important milestone but a long time coming, too long for some biotechnology companies. The near future will show if pharming can regain investor confidence, and whether society and the pharmaceutical industry will accept transgenic livestock as an alternative to more established production methods. There is cause for optimism for biopharmaceuticals represent a considerable and growing market opportunity and animal pharming has made considerable strides. In two decades a novel production platform has been established, new and groundbreaking technologies developed and the necessary regulatory framework put in place. This article highlights some of the obstacles pharming has faced and what the near future might bring.
Keywords
- Chinese Hamster Ovary Cell
- Transgenic Animal
- Bovine Spongiform Encephalopathy
- Nuclear Transfer
- Somatic Cell Nuclear Transfer
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anderson C (1991) “AIDSgate” – a chronology. Nature 353:197–197
Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I, Fletcher A, Will RG, Pocchiari M, Cashman NR, d’Aignaux JH, Cervenáková L, Fradkin J, Schonberger LB, Collins SJ (2000) Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 55:1075–1081
Brüggemann M, Caskey HM, Teale C, Waldmann H, Williams GT, Surani MA, Neuberger MS (1989) A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. Proc Natl Acad Sci USA 86:6709–6713
Clark AJ (1998) The mammary gland as a bioreactor: expression, processing, and production of recombinant proteins. J Mammary Gland Biol Neoplasia 3:337–350
Collick A, Drew J, Penberth J, Bois P, Luckett J, Scaerou F, Jeffreys A, Reik W (1996) Instability of long inverted repeats within mouse transgenes. EMBO J 15:1163–1171
Covarrubias L, Nishida Y, Mintz B (1986) Early Postimplantation Embryo Lethality due to DNA Rearrangements in a Transgenic Mouse Strain. Proc Natl Acad Sci USA 83:6020–6024
Green LL, Hardy MC, Maynard-Currie CE, Tsuda H, Louie DM, Mendez MJ, Abderrahim H, Noguchi M, Smith DH, Zeng Y, David NE, Sasai H, Garza D, Brenner DG, Hales JF, McGuinness RP, Capon DJ, Klapholz S, Jakobovits A (1994) Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs. Nat Genetics 7:13–21
Hammer RE, Pursel VG, Rexroad CE Jr, Wall RJ, Bolt DJ, Ebert KM, Palmiter RD, Brinster RL (1985) Production of transgenic rabbits, sheep and pigs by microinjection. Nature 315:680–683
Heyman Y (2005) Nuclear transfer: a new tool for reproductive biotechnology in cattle. Reprod Nutr Dev 45:353–361
Hofmann A, Kessler B, Ewerling S, Weppert M, Vogg B, Ludwig H, Stojkovic M, Boelhauve M, Brem G, Wolf E, Pfeifer A (2003) Efficient transgenesis in farm animals by lentiviral vectors. EMBO Rep 4:1054–1060
Köhler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495–497
Kuroiwa Y, Kasinathan P, Choi YJ, Naeem R, Tomizuka K, Sullivan EJ, Knott JG, Duteau A, Goldsby RA, Osborne BA, Ishida I, Robl JM (2002) Cloned transchromosomic calves producing human immunoglobulin. Nat Biotechnol 20: 889–894
Kuroiwa Y, Kasinathan P, Matsushita H, Sathiyaselan J, Sullivan EJ, Kakitani M, Tomizuka K, Ishida I, Robl JM (2004) Sequential targeting of the genes encoding immunoglobulin-mu and prion protein in cattle. Nat Genetics 36:775–780
Lawrence S (2007) Billion dollar babies – biotech drugs as blockbusters. Nat Biotechnology 25:380–382
Lillico SG, McGrew MJ, Sherman A, Sang HM (2005) Transgenic chickens as bioreactors for protein-based drugs. Drug Discov Today 10:191–196
Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, Kuo CC, Mashayekh R, Wymore K, McCabe JG, Munoz-O’Regan D, O’Donnell SL, Lapachet ESG, Bengoechea T, Fishwild DM, Carmack CE, Kay RM, Huszar D (1994) Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368:856–859
McCreath KJ, Howcroft J, Campbell KHS, Colman A, Schnieke AE, Kind AJ (2000) Production of gene-targeted sheep by nuclear transfer from cultured somatic cells. Nature 405:1066-1069
Schmidt C (2006) Belated approval of first recombinant protein from animal. Nature Biotechnology 24:877
Schultz WB (1995) Interim definition and elimination of lot-by-lot release for wellcharacterized therapeutic recombinant DNA-derived and monoclonal antibody biotechnology products. US Federal Register 60:63048–63049
Schnieke AE, Kind AJ, RitchieW A, Mycock K, Scott A R, Ritchie M, Wilmut I, Colman A, Campbell KHS (1997) Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts. Science 278:2130–2133
Sinha U, Hancock TE, Nzerem JJ, Lin PH, Tomlinson JE, Wolf DL (1994) Effect of gamma carboxylation on prothrombinase inhibitory activity of catalytically inactive factor XA. Thromb Res 75:427–436
Tomizuka K, Shinohara T, Yoshida H, Uejima H, Ohguma A, Tanaka S, Sato K, Oshimura M, Ishida I (2000) Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci USA 97:722–727
Whitelaw CB, Radcliffe PA, Ritchie WA, Carlisle A, Ellard FM, Pena RN, Rowe J, Clark AJ, King TJ, Mitrophanous KA (2004) Efficient generation of transgenic pigs using equine infectious anaemia virus (EIAV) derived vector. FEBS Lett 571:233–236
Yasunaga H (2007) Risk of authoritarianism: fibrinogen-transmitted hepatitis C in Japan. Lancet 370:2063–2067
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schnieke, A. (2009). Animal Pharming: Past Experience and Future Prospects. In: Engelhard, M., Hagen, K., Boysen, M. (eds) Genetic Engineering in Livestock. Ethics of Science and Technology Assessment, vol 34. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-85843-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-540-85843-0_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-85842-3
Online ISBN: 978-3-540-85843-0
eBook Packages: EngineeringEngineering (R0)